LIfT Biosciences

LIfT Biosciences

Innately curing cancer

2019
Year invested

LIfT Biosciences is committed to developing the world's first cell therapy to destroy all solid tumours, irrespective of strain or mutation. They are achieving this by bringing to market a first in class allogeneic innate cell therapy called Neutrophil Only Leukocyte Infusion Therapy (N-LIfT). Their first mission is to show remission in high unmet need solid tumours by 2022, with an initial focus on pancreatic cancer.

Meet the team

Related articles

Exonar builds momentum to enable enterprises to tackle data deluge - article

Exonar, the world leading data indexing and discovery platform, has today announced that it has secured furthe...

How to survive and thrive in 2021 as a VC firm according to Downing Ventures - article

In 2021, it has never been more important for venture capital firms to be able to differentiate.

Why We Invested In - Ayar Labs

We believe Ayar Labs can address many of the challenges of improving performance while also reducing energy co...